Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections

Infectious Diseases and Therapy

Volumn 5, Issue 1, 2016, Pages

  Brade, Karrine D ^b   Rybak, Jeffrey M ^c   Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b ST VINCENT HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute bacterial skin and skin structure infection; Lipoglycopeptide; Oritavancin

Indexed keywords

AMPICILLIN; CEFTAROLINE; CEFTRIAXONE; DAPTOMYCIN; LINEZOLID; OMEPRAZOLE; ORITAVANCIN; VANCOMYCIN; WARFARIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CELLULITIS; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; GRAM POSITIVE INFECTION; HEADACHE; HUMAN; IATROGENIC DISEASE; LIMB ABSCESS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OSTEOMYELITIS; PHARMACODYNAMICS; PHARMACOKINETIC ASSAY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN ABSCESS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 84977126738     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-016-0103-4     Document Type: Review

References (45)

1. Edelsberg J, Weycker D, Barron R, Li X, Wu H, Oster G, et al. Prevalence of antibiotic resistance in US hospitals. Diagn Microbiol Infect Dis. 2014;78(3):255–62.
2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14.
3. Cooper RD, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot. 1996;49(6):575–81.
4. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother. 1997;41(10):2165–72.
5. Munch D, Engels I, Muller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G, et al. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother. 2015;59(2):772–81.
6. Baptista M, Depardieu F, Courvalin P, Arthur M. Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Antimicrob Agents Chemother. 1996;40(10):2291–5.
7. Reipert A, Ehlert K, Kast T, Bierbaum G. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob Agents Chemother. 2003;47(2):568–76.
8. Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008;377(1):281–93.
9. Kim SJ, Matsuoka S, Patti GJ, Schaefer J. Vancomycin derivative with damaged d-Ala-d-Ala binding cleft binds to cross-linked peptidoglycan in the cell wall of Staphylococcus aureus. Biochemistry. 2008;47(12):3822–31.
10. Kim SJ, Singh M, Schaefer J. Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus. J Mol Biol. 2009;391(2):414–25.
11. Patti GJ, Kim SJ, Yu TY, Dietrich E, Tanaka KS, Parr TR Jr, et al. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J Mol Biol. 2009;392(5):1178–91.
12. Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54(12):5369–71.
13. Belley A, Lalonde-Seguin F, Arhin FF, Moeck G, editors. In vitro bactericidal activity of oritavancin, dalbavancin and vancomycin against non-dividing methicillin-resistant Staphylococcus aureus (MRSA). Interscience conference of antimicrobial agents and chemotherapy/international congress of chemotherapy and infection 2015; 2015; San Diego, CA.
14. McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T Jr, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2009;63(6):1191–9.
15. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–13). J Antimicrob Chemother. 2015;70(2):498–504.
16. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Oritavancin activity against Staphylococcus aureus causing invasive infections in US and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother. 2014;58(5):2921–4.
17. Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009–2010. Antimicrob Agents Chemother. 2012;56(3):1639–42.
18. Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68(1):164–7.
19. Orbactiv (oritavancin) for injection [package insert]. Parsippany, NJ: Medicines Company; Rev 08/14.
20. Arhin FF, Sarmiento I, Parr TR Jr, Moeck G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother. 2009;64(4):868–70.
21. Smith JR, Yim J, Raul A, Rybak MJ. Beta-lactams (BLs) enhance oritavancin (ORI) activity against methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to daptomycin (DAP) and vancomycin (VAN) and vancomycin-resistant enterococci (VRE). Interscience conference of antimicrobial agents and chemotherapy/international congress of chemotherapy and infection. San Diego, California. 2015.
22. Vidaillac C, Parra-Ruiz J, Rybak MJ. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Diagn Microbiol Infect Dis. 2011;71(4):470–3.
23. O’Connor R, Baines SD, Freeman J, Wilcox MH. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J Antimicrob Chemother. 2008;62(4):762–5.
24. Chilton CH, Freeman J, Baines SD, Crowther GS, Nicholson S, Wilcox MH. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. J Antimicrob Chemother. 2013;68(9):2078–82.
25. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004;50(2):95–102.
26. Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015;59(6):3365–72.
27. Rowe PA, Brown TJ. Protein binding of 14C-oritavancin. 41st interscience conference on antimicrobial agents and chemotherapy; Washingthon DC: American Society for Microbiology; 2001.
28. Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005;49(1):148–52.
29. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53(10):4422–8.
30. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003;47(5):1700–6.
31. Lehoux D, Laquerre K, Ostiguy V, Fadhil I, Malouin M, Cadieux C, et al., editors. Comparative efficacy of oritavancin (ORI) against methicillin -sensitive and -resistant Staphylococcus aureus strains in a neutropenic-mouse thigh infection model. 49th interscience conference on antimicrobial agents and chemotherapy; 2009. San Francisco, CA.
32. Okusanya OO, Lehoux D, van Wart S, Rafai Far A, Forrest A, Moeck G, et al., editors. Pharmacokinetics (PK) and pharmacokinetics–pharmacodynamics (PK–PD) of oritavancin (ORI) against Staphylococcus aureus (SA) in a neutropenic murine thigh-infection model. 49th interscience conference on antimicrobial agents and chemotherapy; 2009. San Francisco, CA.
33. Dunbar LM, Milata J, McClure T, Wasilewski MM, Team SS. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55(7):3476–84.
34. Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Antimicrob Agents Chemother. 2013;57(1):205–11.
35. Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53(3):918–25.
36. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998;42(4):981–3.
37. Gerber J, Smirnov A, Wellmer A, Ragheb J, Prange J, Schutz E, et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother. 2001;45(7):2169–72.
38. Rupp ME, Fey PD, Longo GM. Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother. 2001;47(5):705–7.
39. Saleh-Mghir A, Lefort A, Petegnief Y, Dautrey S, Vallois JM, Le Guludec D, et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 1999;43(1):115–20.
40. Lehoux D, Ostiguy V, Cadieux C, Malouin M, Belanger O, Rafai Far A, et al. Oritavancin pharmacokinetics and bone penetration in rabbits. Antimicrob Agents Chemother. 2015;59(10):6501-5.
41. Freeman J, Marquis M, Crowther GS, Todhunter SL, Fawley WN, Chilton CH, et al. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. J Antimicrob Chemother. 2012;67(12):2919–26.
42. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–62.
43. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180–90.
44. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2014;60(2):254–62.
45. Greenblatt DJ ZY, Duan SX, et al. Effect of oritavancin on human cytochrome P450 in vitro [poster no. A1-1284]. 49th interscience conference on antimicrobial agents and chemotherapy; September 12–15; San Francisco; 2009.